Holen Sie sich die Stockscreener-App
1.60
4.19%
-0.07
Schlusskurs vom Vortag:
$1.67
Offen:
$1.65
24-Stunden-Volumen:
555.21K
Relative Volume:
0.87
Marktkapitalisierung:
$73.17M
Einnahmen:
$19.94M
Nettoeinkommen (Verlust:
$-37.37M
KGV:
-1.5385
EPS:
-1.04
Netto-Cashflow:
$-33.38M
1W Leistung:
-1.84%
1M Leistung:
+14.29%
6M Leistung:
+74.10%
1J Leistung:
-21.95%
1-Tages-Spanne:
$1.58
$1.68
1-Wochen-Bereich:
$1.56
$1.83
52-Wochen-Spanne:
$0.595
$4.18
Werewolf Therapeutics Inc Stock (HOWL) Company Profile
Firmenname
Werewolf Therapeutics Inc
Sektor
Branche
Telefon
617-952-0555
Adresse
200 TALCOTT AVENUE, WATERTOWN
Vergleichen Sie HOWL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HOWL
Werewolf Therapeutics Inc
|
1.60 | 76.37M | 19.94M | -37.37M | -33.38M | -1.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
416.81 | 104.76B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.67 | 63.06B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
578.05 | 60.32B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
843.66 | 51.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
165.76 | 34.49B | 398.11M | -1.03B | -868.57M | -5.7032 |
Werewolf Therapeutics Inc Stock (HOWL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-04-03 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-08-24 | Eingeleitet | Wedbush | Outperform |
| 2023-06-06 | Fortgesetzt | Jefferies | Buy |
| 2021-09-10 | Eingeleitet | BofA Securities | Buy |
| 2021-05-25 | Eingeleitet | Evercore ISI | Outperform |
| 2021-05-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-25 | Eingeleitet | Jefferies | Buy |
| 2021-05-25 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Werewolf Therapeutics Inc Aktie (HOWL) Neueste Nachrichten
Analyzing recovery setups for Werewolf Therapeutics Inc. investorsPortfolio Growth Summary & Community Verified Trade Alerts - newser.com
Will Werewolf Therapeutics Inc. stock outperform growth indexesMarket Risk Report & Fast Gain Stock Trading Tips - newser.com
Using data tools to time your Werewolf Therapeutics Inc. exitTrade Analysis Summary & Capital Efficiency Focused Strategies - newser.com
Identifying reversal signals in Werewolf Therapeutics Inc.2025 Risk Factors & Intraday High Probability Alerts - newser.com
Werewolf Therapeutics Inc. stock trendline breakdown2025 Volatility Report & Free Expert Verified Stock Movement Alerts - newser.com
Intraday pattern recognizer results for Werewolf Therapeutics Inc.Quarterly Portfolio Review & Weekly Hot Stock Watchlists - newser.com
Predicting Werewolf Therapeutics Inc. trend using moving averagesSwing Trade & Reliable Volume Spike Alerts - newser.com
How to recover losses in Werewolf Therapeutics Inc. stockJuly 2025 Catalysts & Weekly High Momentum Picks - newser.com
Will Werewolf Therapeutics Inc. stock maintain dividend yieldQuarterly Portfolio Report & AI Enhanced Trade Execution Alerts - newser.com
Weiss Ratings Reaffirms "Sell (D-)" Rating for Werewolf Therapeutics (NASDAQ:HOWL) - MarketBeat
How high can Werewolf Therapeutics Inc. stock goEarnings Summary Report & Reliable Intraday Trade Alerts - newser.com
Werewolf Therapeutics receives FDA Fast Track for melanoma therapy By Investing.com - Investing.com Nigeria
Werewolf Therapeutics Says Investigational Melanoma Therapy WTX-124 Receives US FDA Fast Track Designation - MarketScreener
Werewolf Therapeutics receives FDA Fast Track for melanoma therapy - Investing.com
Werewolf Therapeutics receives fast track designation from the U.S. FDA for WTX-124, an investigational therapy for the treatment of cancer - MarketScreener
Werewolf Therapeutics Receives Fast Track Designation from - GlobeNewswire
Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer - Yahoo Finance
Fast Track for WTX-124: Werewolf advances IL-2 INDUKINE for relapsed cutaneous melanoma - Stock Titan
Werewolf Therapeutics Faces Nasdaq Compliance Challenge - TipRanks
Werewolf Therapeutics notifies Nasdaq of audit committee noncompliance after board member’s passing - Investing.com
Using flow based indicators on Werewolf Therapeutics Inc.Market Growth Summary & Risk Managed Trade Strategies - newser.com
Will earnings trigger a reversal in Werewolf Therapeutics Inc.2025 Institutional Moves & Long-Term Safe Investment Ideas - newser.com
Werewolf Therapeutics Inc. stock chart pattern explainedWeekly Trade Report & AI Enhanced Trade Execution Alerts - newser.com
Jefferies Initiates Werewolf Therapeutics(HOWL.US) With Buy Rating, Announces Target Price $4 - 富途牛牛
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting - GlobeNewswire
Werewolf Therapeutics to Present Innovative Research at SITC 40th Annual Meeting - Quiver Quantitative
3 Posters: Werewolf Therapeutics to Present WTX-124, mWTX-330 Research at SITC Nov 5-9 - Stock Titan
Published on: 2025-09-30 05:19:05 - newser.com
Goldman Sachs Group Inc. Has $109,000 Stock Holdings in Werewolf Therapeutics, Inc. $HOWL - Defense World
Published on: 2025-09-30 01:50:53 - newser.com
Finanzdaten der Werewolf Therapeutics Inc-Aktie (HOWL)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.84%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):